GlassScriptPhysician profile
Jonathan A Schneider
NPI 1801943600
$12,427.10
in general payments reported to CMS, 2019-2025
45 companies · $2,998 in 2025
The $2,998 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,472 · 2020: $2,142 · 2021: $1,662 · 2022: $1,768 · 2023: $1,458 · 2024: $926 · 2025: $2,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,370 · Travel and Lodging: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,370.28 |
| Travel and Lodging | $1,012.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $3,307.32 | 2019-2024 | Esophyx |
| Abbvie INC. | $2,927.15 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Kerecis Limited | $1,012.01 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Conmed Corporation | $676.66 | 2019-2025 | Conmed Biliary, Conmed Hemostasis |
| Medtronic, INC. | $595.99 | 2021-2023 | Endoflip, Gi Genius |
| Janssen Biotech, INC. | $542.93 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $356.03 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $348.70 | 2019-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $324.90 | 2021-2025 | Apollo Esg Nxt System |
| Pfizer INC. | $271.10 | 2021-2025 | |
| Gi Supply, INC. | $190.99 | 2021 | |
| Merit Medical Systems INC | $176.61 | 2025 | Esophyx, Endomaxx Stent and Delivery System, Elation Balloon Dilator |
| Shionogi INC | $161.70 | 2019-2020 | |
| Qol Medical, LLC | $155.87 | 2020-2025 | Sucraid |
| Celgene Corporation | $134.37 | 2021-2024 | Zeposia |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.